论文部分内容阅读
美国临床肿瘤学会(ASCO)年会近日在芝加哥召开。在刚刚结束的转移性乳腺癌口头报告专场汇集该领域本年度最值得关注的研究。中国医学科学院肿瘤医院王佳玉医生对这些最新数据进行分析点评。MARIANNE研究是一线T-DM1+/-帕妥珠单抗对比曲妥珠单抗联合紫杉类治疗HER2阳性晚期乳腺癌(MBC)的随机Ⅲ期临床研究。该研究中,入组的HER2阳性MBC患者均经中心实验室检测确认HER2阳性(IHC3+or ISH+),且均为初治晚期或经紫
The American Society of Clinical Oncology (ASCO) annual meeting was held in Chicago recently. The just-concluded oral report on metastatic breast cancer focused on this area’s most noteworthy research this year. Dr. Wang Jiayu from the Cancer Hospital of the Chinese Academy of Medical Sciences reviewed the latest data. The MARIANNE study is a randomized phase III clinical study of first-line T-DM1 +/- pertuzumab vs. trastuzumab plus taxanes for the treatment of HER2-positive advanced breast cancer (MBC). In this study, HER2 positive MBC patients who were enrolled in the group were all confirmed by the central laboratory to be HER2 positive (IHC3+or ISH+), both of which were late treatment or purple.